Security
Pyxis Oncology, Inc. Common Stock · PYXS
PYXSNASDAQCommon stockCurrentCIK 1782223Updated Oct 4, 2026
PYXS price & chart
Loading TradingView…
NASDAQ:PYXS on TradingView ↗About the company
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.
In the news
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering ↗
Recent filings
SCHEDULE 13G/A - filed by GordonMD Global Investments LP regarding Pyxis Oncology, Inc.
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
424B5 filing
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 91,520,000Source | 157,181,000Source | 173,726,000Source | 211,379,000Source |
| Property, Plant and Equipment, NetUSD | 7,997,000Source | 9,899,000Source | 11,872,000Source | 11,165,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 0Source | 2,600,000Source | 24,308,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,422,000Source | 19,473,000Source | 9,664,000Source | 179,293,000Source |
| Assets, CurrentUSD | 72,105,000Source | 132,440,000Source | 124,604,000Source | 186,612,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,776,000Source | 4,037,000Source | 3,834,000Source | 5,847,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,418,000Source | 12,242,000Source | 12,942,000Source | 13,602,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 38,112,000Source | 36,430,000Source | 48,022,000Source | 50,555,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 63,000Source | 60,000Source | 45,000Source | 34,000Source |
| Additional Paid in CapitalUSD | 496,469,000Source | 484,077,000Source | 411,821,000Source | 373,225,000Source |
| Retained Earnings (Accumulated Deficit)USD | -443,177,000Source | -363,556,000Source | -286,225,000Source | -212,435,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 53,000Source | 170,000Source | 63,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 53,408,000Source | 120,751,000Source | 125,704,000Source | 160,824,000Source |
| Liabilities and EquityUSD | 91,520,000Source | 157,181,000Source | 173,726,000Source | 211,379,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 21,131,000Source | 17,680,000Source | 25,759,000Source | 31,634,000Source |
| Operating Lease, Liability, CurrentUSD | 1,692,000Source | 1,450,000Source | 1,232,000Source | — |
| Accounts Payable, CurrentUSD | 10,885,000Source | 4,859,000Source | 3,896,000Source | 7,097,000Source |
| Operating Lease, Liability, NoncurrentUSD | 16,958,000Source | 18,650,000Source | 20,099,000Source | 18,921,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 0Source | 2,164,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 8,554,000Source | 11,371,000Source | 12,971,000Source | 24,537,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 66,900,000Source | 126,900,000Source | 119,300,000Source | — |
| Deferred Tax Liabilities, NetUSD | 0Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -79,621,000Source | -77,331,000Source | -73,790,000Source | -120,717,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 4,511,000Source | 2,982,000Source | 1,927,000Source | 709,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 11,801,000Source | 12,945,000Source | 16,946,000Source | 15,764,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 6,026,000Source | 1,200,000Source | -3,507,000Source | -8,328,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -63,502,000Source | -57,672,000Source | -70,709,000Source | -89,335,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 58,857,000Source | 8,155,000Source | -104,849,000Source | -6,399,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 9,000Source | 237,000Source | 6,726,000Source | 6,399,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 148,000Source | 240,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 594,000Source | 59,326,000Source | 5,929,000Source | 183,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -4,051,000Source | 9,809,000Source | -169,629,000Source | -95,551,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 16,894,000Source | 20,945,000Source | 11,136,000Source | 180,765,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 91,000Source | 10,000Source | — | — |
| Income Taxes Paid, NetUSD | 1,379,000Source | 164,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 11,801,000Source | 12,945,000Source | 16,946,000Source | 11,947,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 66,900,000Source | 126,900,000Source | 119,300,000Source | — |
| DepreciationUSD | 1,900,000Source | 2,000,000Source | 1,800,000Source | — |
| General and Administrative ExpenseUSD | 22,194,000Source | 25,420,000Source | 32,610,000Source | 37,352,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 20,964,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 1,386,000Source | -2,164,000Source | — | — |
| Investment Income, InterestUSD | 650,000Source | 930,000Source | 1,842,000Source | 2,764,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | -117,000Source | 107,000Source | 63,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -79,621,000Source | -77,331,000Source | -73,790,000Source | -120,717,000Source |
| Nonoperating Income (Expense)USD | 6,185,000Source | 9,965,000Source | 8,406,000Source | 2,764,000Source |
| Operating ExpensesUSD | — | — | 82,196,000Source | 123,481,000Source |
| Operating Lease, ExpenseUSD | 824,000Source | 700,000Source | 660,000Source | 1,127,000Source |
| Proceeds from Stock Options ExercisedUSD | 632,000Source | 296,000Source | 120,000Source | 183,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 13,858,000Source | 16,146,000Source | — | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -84,420,000Source | -89,460,000Source | -82,196,000Source | -123,481,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -78,235,000Source | -79,495,000Source | — | — |
| Income Tax Expense (Benefit)USD | 1,386,000Source | -2,164,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -79,621,000Source | -77,331,000Source | -73,790,000Source | -120,717,000Source |
| Earnings Per Share, BasicUSD per share | -1.28Source | -1.32Source | -1.85Source | -3.65Source |
| Earnings Per Share, DilutedUSD per share | -1.28Source | -1.32Source | -1.85Source | -3.65Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 62,143,166Source | 58,445,765Source | 39,904,603Source | 33,033,081Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 62,143,166Source | 58,445,765Source | 39,904,603Source | 33,033,081Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 1,386,000Source | — | — | — |
| General and Administrative ExpenseUSD | 22,194,000Source | 25,420,000Source | 32,610,000Source | 37,352,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source |
| Investment Income, InterestUSD | 650,000Source | 930,000Source | 1,842,000Source | 2,764,000Source |
| Investment Income, NetUSD | 3,610,000Source | 7,039,000Source | 6,630,000Source | — |
| Nonoperating Income (Expense)USD | 6,185,000Source | 9,965,000Source | 8,406,000Source | 2,764,000Source |
| Operating ExpensesUSD | — | — | 82,196,000Source | 123,481,000Source |
| Operating Lease, ExpenseUSD | 824,000Source | 700,000Source | 660,000Source | 1,127,000Source |
| Research and Development ExpenseUSD | 73,696,000Source | 58,747,000Source | 49,586,000Source | 86,129,000Source |
Offerings
Registration 333-298461
Filing attachments
pyxs-ex99_1.htm · 8-K · 2026-09-09
EX-99.1 2 pyxs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups Substantial …
Read attachment ↗pyxs-ex99_2.htm · 8-K · 2026-09-09
EX-99.2 3 pyxs-ex99_2.htm EX-99.2 Pyxis Oncology MICVO Clinical Update September 9, 2026 Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation, including without limitation statements regarding the Company’s plans to develop,…
Read attachment ↗pyxs-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 pyxs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board Leadership transition reflects continued focus on advancing MICVO through key clinical milestones BOSTON, September 8, 2026 (GLOBE NEWSWIRE) - Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for di…
Read attachment ↗pyxs-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 pyxs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO Phase 1/2 combination study with pembrolizumab in 1L R/M HNSCC on track to be reported in the fourth quar…
Read attachment ↗pyxs-ex4_1.htm · 8-K · 2026-07-02
EX-4.1 2 pyxs-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II…
Read attachment ↗pyxs-ex99_1.htm · 8-K · 2026-07-02
EX-99.1 5 pyxs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase 1 monotherapy data in Fall 2026 and updated Phase 1/2 combination data in the fourth quarter of 2026 Financing led b…
Read attachment ↗